Author: OurCrowd

[Polarisqb in Quantum Zeitgeist] D-Wave powers PolarisQB software reducing drug design time from years to hours

Jan 13, 2026 |

Polaris Quantum Biotech (PolarisQB) developed QuADD, the first drug discovery software platform built around quantum computing for lead identification. Utilizing a D-Wave Advantage system with over 5000 qubits, QuADD reduces drug design time from years to just hours. This platform can explore up to 10^30 theoretical molecules, optimizing for key properties and accelerating early-stage drug discovery. Watch...

Read More

[Lifeward in PR Newswire] Oramed and Lifeward announce strategic transaction

Jan 13, 2026 |

NEW YORK, Jan. 13, 2026 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (“Oramed”) and Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward”) today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed’s proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions.  Read more...

Read More

[Axiom Space in Memesita] Axiom Space Station: New plan for faster, independent orbit

Jan 13, 2026 |

CAPE CANAVERAL, FL – Forget gradual transitions. Axiom Space is hitting the gas pedal on its plans for a fully independent commercial space station, accelerating its timeline and signaling a major shift in the future of low Earth orbit (LEO). The Houston-based company revealed a revised assembly plan aiming for a functional, free-flying habitat by late 2025 – a move that dramatically reduces reliance on the aging International Space Station (ISS) and throws down the gauntlet in the burgeoning private space station race. Read...

Read More